Tokyo · Stocky rates: Avoid

CKD CORP (6407.T)

¥5,510.00 ▼ -1.25% as of 24 Aug, 13:39

Stocky turns companies like CKD CORP into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.

Try Stocky free →
38
/ 100
Avoid

What Stocky thinks

Avoid. 6407.T scores 38/100 overall, with weak Growth Compounder (42/100) and middling Value Compounder (52/100) marks indicating neither compelling growth nor a margin-of-safety valuation case. Leadership Alignment (53.3/100) and a Vulnerable profile signal structural headwinds that outweigh any near-term appeal.

Compounder Score
52/100
Business quality — profitability, growth, capital efficiency.
Leadership Alignment
53/100
Founder-led, insider ownership, capital allocation history.
Vulnerability
0/100
Downside resilience — customer concentration, supply chain, refinancing risk.
Value Score
52/100
Valuation vs peers and history — is this a good price to pay?

What Stocky gives investors that other tools don't

Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for CKD CORP:

38
VERDICT

Stocky Verdict — one score, everything

Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 38/100, you know instantly whether to dig deeper or skip.

Rated
MOAT

Moat Score — is there a real edge?

Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.

53
LEADER

Leadership Alignment — is management on your side?

Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.

0
RISK

Vulnerability Profile — what could break?

Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.

Elite
TRACK

Track Record — does the system work?

Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.

24/7
ALERTS

Alerts + Portfolio insights

Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.

CKD CORP (6407.T) — frequently asked

Is CKD CORP (6407.T) a good investment right now?

Stocky rates CKD CORP (6407.T) at 38/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. 6407.T scores 38/100 overall, with weak Growth Compounder (42/100) and middling Value Compounder (52/100) marks indicating neither compelling growth nor a margin-of-safety valuation case. Leadership Alignment (53.3/100) and a Vulnera

What is 6407.T's Stocky Verdict?

6407.T's current Stocky Verdict is 38/100, placing it in the "Avoid" band. This composite combines a 52/100 Compounder score, 53/100 Leadership, Moat rating, and analyst signal.

Does CKD CORP have a competitive moat?

Stocky hasn't finalised a Moat Score for CKD CORP yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.

Is CKD CORP's leadership aligned with shareholders?

CKD CORP scores 53/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.

What are the biggest risks to 6407.T?

CKD CORP's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to CKD CORP.

This is just the surface. See the whole picture on CKD CORP.

Sign up free and unlock the full analysis on 6407.T — the same tools professional analysts use, personalised to your portfolio:

  • Every analyst covering 6407.T — full list with star ratings, price targets, historical hit-rate. Not just the top 3 you see above.
  • Full Vulnerability Profile — customer concentration, refinancing walls, stress-test scenarios (-20% revenue, +200bp rates) modelled specifically for 6407.T.
  • Bull & bear thesis — the AI-written counter-argument every retail investor forgets to read.
  • Portfolio fit check — how 6407.T changes your sector concentration, correlation and Verdict-weighted quality.
  • Ask Stocky AI — "What are the biggest 3-year risks to 6407.T?" · "Is 6407.T overvalued vs its 5-year median?" · unlimited follow-ups on your portfolio.
  • Live alerts — analyst target changes, insider buys, big moves — the day they happen.
Start free · 14 days Plus, no card →

Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.

STOCKY VERDICT
38
/ 100 · Avoid

See CKD CORP the Stocky way

This page is just a preview. Open the live, interactive version for the full picture:

Stocky Verdict
A plain-English Buy / Hold / Sell score out of 100.
Compounder & Value scores
How strong the business is — and whether it looks cheap.
Interactive charts
1M to 5Y price history with company events plotted on it.
Top analyst targets
What the best-rated Wall Street analysts expect next.
What if? simulator
See what an investment in 6407.T would be worth today.
Practice portfolio
Buy 6407.T with virtual money and track it — zero risk.
Free · no real money · learn by doing Open 6407.T in Stocky →

Or jump straight to the interactive dashboard for 6407.T in the app.